Byline: Market Analysis & Forecast CareDx is one of the more intriguing healthcare stocks in the diagnostics sector. For years, the company was viewed as a high-growth precision medicine leader. Then regulatory concerns, reimbursement uncertainty , and slowing growth sent the stock into a steep decline. Today, management's message is very different: 👉 focus on profitability, transplant market leadership, and rebuilding growth. The key question for investors: 👉 Is CareDx a turnaround opportunity , or has the best growth already passed? The News: Recovery Is Gaining Momentum Recent leadership commentary has focused on: Expanding transplant testing volumes Improving reimbursement visibility Operational efficiency Margin improvement Long-term transplant market growth Management continues emphasizing that transplant monitoring remains significantly underpenetrated globally. The Real Story: Dominating a Specialized Market CareDx specializes in: Organ t...